Rasagiline [
N-propargyl-1R(+)-aminoindan; TVP1012] is a potent irreversible
monoamine oxidase (
MAO) inhibitor with selectivity for type B of the
enzyme, which is being developed for treatment of
Parkinson's disease. In this study we examined effects of
rasagiline on CNS monoamine levels, modification of behavioural response to
L-tryptophan,
fluoxetine and
L-DOPA, and reversal of
reserpine syndrome.
Reserpine-induced ptosis was reversed by
rasagiline at doses above 2 mg x kg(-1) i.p., which inhibit
MAO-A as well as
MAO-B, but not at
MAO-B-selective doses. However, combination of
rasagiline (10 mg x kg(-1) i.p.) with
L-DOPA or
L-tryptophan (50 mg x kg(-1) i.p.), or
rasagiline (10 mg x kg(-1) p.o.) with
fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both
MAO-A and
MAO-B by
tranylcypromine together with the monoamine precursors. Following
oral administration, levels of
noradrenaline (NA),
5-hydroxytryptamine (5-HT) and
dopamine (DA) were unaffected in hippocampus and striatum after single doses of
rasagiline up to 2 mg x kg(-1). Following chronic
oral administration (21 days, one dose daily), levels of NA,
5-HT and DA in hippocampus and striatum were unaffected by
rasagiline at doses up to 1 mg x kg(-1).
Rasagiline does not modify CNS monoamine tissue levels or monoamine-induced behavioural syndromes at doses which selectively inhibit
MAO-B but not
MAO-A.